Docoh
Loading...

CRVS Corvus Pharmaceuticals

APP
Utility
Humanized ANTI-CD73 Antibodies
19 Aug 21
Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73.
Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
Filed: 24 Sep 20
APP
Utility
Methods for Detecting and Treating Cancers Having Adenosine Pathway Activation
19 Aug 21
This disclosure relates to methods for detecting a level of expression of one or more genes in a subject having or suspected of having cancer, and optionally treating the subject with an adenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist in combination with a PD-1 inhibitor and/or a PD-L1 inhibitor, to treat the cancer.
Stephen Willingham, Andrew Hotson, Richard A. Miller
Filed: 12 Jul 19
APP
Utility
Methods for Detecting and Treating Cancers Having Adenosine Pathway Activation
19 Aug 21
This disclosure relates to methods for detecting a level of expression of one or more genes (or proteins) in a subject having or suspected of having cancer, and optionally treating the subject with an adenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist, to treat the cancer.
Stephen Willingham, Andrew Hotson, Richard A. Miller
Filed: 12 Jul 19
APP
Utility
ANTI-CD73 Antibodies
22 Jul 21
Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same.
Emily Piccione Griffin, Richard A. Miller, Ian McCaffery
Filed: 27 Aug 20
GRANT
Utility
Methods of treating cancer
22 Jun 21
Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the subject comprises an elevated level of CD8+ tumor infiltrating lymphocytes relative to a control, the subject comprises an elevated level of T-effector gene signature relative to a control, the subject comprises an increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, the cancer tumor comprises an elevated level of PD-L1 relative to a control, and/or the cancer tumor or the blood of the subject comprises an elevated level of CD73 relative to a control.
Andrew Hotson, Richard A. Miller, Ian Mccaffery, Stephen Willingham
Filed: 4 Apr 18
APP
Utility
Methods of Treating Cancer
27 May 21
Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist or a combination of an adenosine-A2A (A2A) receptor antagonist and a programmed cell death protein 1 (PD-1) signaling pathway inhibitor.
Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian Mccaffery, Andrew Hotson
Filed: 17 Dec 20
GRANT
Utility
Compounds and methods for modulating interleukin-2-inducible t-cell kinase
18 May 21
Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.
Ryan Hudson, Anne-Marie Beausoleil
Filed: 3 Nov 17
APP
Utility
Pharmaceutical Formulations
4 Mar 21
The disclosure provides, inter alia, pharmaceutical compositions comprising micronized drug particles of adenosine A2A receptor antagonists, and methods of treating cancer using the pharmaceutical compositions.
Jingrong Xu, William Jones, Felicia Flicker, Bret Berner
Filed: 1 Feb 19
GRANT
Utility
Methods of treating cancer
9 Feb 21
Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor.
Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian McCaffery, Andrew Hotson
Filed: 22 Dec 16
APP
Utility
Adenosine Pathway Inhibitors for Cancer Treatment
14 Jan 21
Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors.
Richard A. Miller, Ian Mccaffery, Andrew Hotson
Filed: 6 Nov 18
GRANT
Utility
Compounds and methods for modulating bruton's tyrosine kinase
21 Dec 20
Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.
Ryan Hudson, Anne-Marie Beausoleil, Richard A. Miller, Erik Verner
Filed: 9 Mar 17
GRANT
Utility
Humanized anti-CD73 antibodies
2 Nov 20
Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73.
Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
Filed: 8 Dec 16
GRANT
Utility
Anti-CD73 antibodies
5 Oct 20
Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same.
Emily Piccione Griffin, Richard A. Miller, Ian McCaffery
Filed: 10 Jul 17
APP
Utility
Methods of Treating Cancer
23 Sep 20
Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the subject comprises an elevated level of CD8+ tumor infiltrating lymphocytes relative to a control, the subject comprises an elevated level of T-effector gene signature relative to a control, the subject comprises an increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, the cancer tumor comprises an elevated level of PD-L1 relative to a control, and/or the cancer tumor or the blood of the subject comprises an elevated level of CD73 relative to a control.
Andrew Hotson, Richard A. Miller, Ian Mccaffery, Stephen Willingham
Filed: 3 Apr 18
APP
Utility
Combination Therapy for Cancer Treatment
19 Aug 20
Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors and PD-1 pathway inhibitors.
Richard A. Miller, Ian Mccaffery, Andrew Hotson
Filed: 5 Nov 18
GRANT
Utility
Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof
18 May 20
Provided herein are, inter alia, methods for making triazolo[4,5]pyramidine derivatives and intermediates thereof that are useful for treating diseases.
Kolbot By, William Benton Jones, Bradley Hamilton Wolfe
Filed: 29 Mar 18
APP
Utility
Compounds and Methods for Modulating Adenosine A2B Receptor and Adenosine A2A Receptor
11 Mar 20
Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors.
Zhihong Li, Lubov Konstantinovna Filonova, Erik Verner
Filed: 29 Aug 19
APP
Utility
Compounds and Methods for Modulating INTERLEUKIN-2-INDUCIBLE T-cell Kinase
11 Dec 19
Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.
Ryan HUDSON, Anne-Marie BEAUSOLEIL
Filed: 2 Nov 17
  • 1
Patents are sorted by USPTO publication date, most recent first